spacer
home > epc > summer 2002 > leveraging web-based clinical trials to support the marketing platform
PUBLICATIONS
European Pharmaceutical Contractor

Leveraging Web-Based Clinical Trials to Support the Marketing Platform

In an increasingly competitive environment, pharmaceutical drug and device manufacturers cannot easily tolerate delays in achieving peak sales following launch of their products. Additionally, there are more and more requirements being placed upon manufacturers to examine the safety of their products in the marketplace, the results of which can sometimes pose problems or even post-marketing product withdrawal. In the past, there was often time within a traditional product development programme to generate useful data to enhance market penetration. But now, the emphasis is on speeding products through the development process to market in order to realise a revenue stream as early as possible. Consequently, more is being asked of individual clinical trials, both pre- and post-approval to fulfil both development and marketing needs.

This article explores how new web-based clinical trial technologies can be used to meet the marketing needs at the time of product launch and beyond.

Fifteen years ago, a typical conversation between the product manager and the clinical research manager was along the lines of, 'We will probably get approval for product X in the next few months and marketing want to do some trials with our opinion leaders so they get experience with the product and act as our advocates. What can the clinical department do for us?' The usual response was to scratch around for a reasonable scientific question to be asked, whilst exposing as many patients and doctors to the product as possible.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Michael Bowden, Managing Director of the European Arm, Dr Timothy Sprosen, Director of Product Development of the European Arm, and Steve Mackenzie-Lawrie, Director of Sales and Marketing of Health Decisions

Dr Michael Bowden is the Managing Director of the European arm of Health Decisions, a global contract research organisation that uses the Internet extensively in its clinical development programmes. Michael has worked in the pharmaceutical industry for more than 15 years in various medical marketing and development roles and is a regular contributor of articles on the practical use of technology in clinical trials.

Dr Timothy Sprosen is the Director of Product Development of the European arm of Health Decisions. He has over a decade of experience in the pharmaceutical industry, notably in conducting late phase and post-marketing trials and product support.

Steve Mackenzie-Lawrie is Director of Sales & Marketing at Health Decisions and has a wealth of experience in the development and execution of pre- and post-launch marketing and communication programmes. Steve is a strong advocate and practitioner of establishing the link between clinical trial programmes and the marketing and commercialisation of new products.
spacer
Dr Michael Bowden
spacer
spacer
spacer
Dr Timothy Sprosen
spacer
spacer
spacer
Steve Mackenzie-Lawrie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health and ActiGraph simplify clinical trial activity and sleep monitoring for patients, sites, and sponsors with their new integration

Philadelphia, PA – November 14, 2019: Signant Health, formerly CRF Health and Bracket, is proud to announce that it has integrated its industry leading eCOA platform TrialMax®, with ActiGraph’s CentrePoint system. The integration, which includes ActiGraph’s FDA 510(k) cleared sensors, helps simplify the process of collecting and monitoring real-world activity, mobility, and sleep outcomes data for patients and researchers.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement